P1.03-34 Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.715
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy
OncologyPharmacology
2019English

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2017English

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

Annals of Oncology
MedicineOncologyHematology
2019English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PC04.02 Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy